VEGF Inhibition Market Reviewed in New Report Now Available at MarketPublishers.com

Share Article

Vascular Endothelial Growth Factor (VEGF) is the most prominent inducer of angiogenesis. It undergoes a careful study and is observed in a number of cancers. Treatment VEGFs via inhibition of such VEGFs as bevacizumab turned into a standard for a large fraction of cancers. New research report “VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011” developed by Biopharm Reports has been recently published by Market Publishers Ltd.

marketpublishers.com

Market Publishers Ltd

Vascular Endothelial Growth Factor (VEGF) is the most prominent inducer of angiogenesis. It undergoes a careful study and is observed in a number of cancers. Treatment VEGFs via inhibition of such VEGFs as bevacizumab (Avastin®) turned into a standard for a large fraction of cancers. Nevertheless, the therapy is not applicable to all types of the disease and patients. This results in a necessity of biomarkers usage, enabling to indicate patients who may undertake such therapy.

New research report “VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011” developed by Biopharm Reports has been recently published by Market Publishers Ltd.

Report Details:

Title: VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011
Published: October, 2011
Pages: 97
Price: US$ 1,520
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/vegf_inhibition_therapy_indicating_n_prognostic_biomarkers_2011.html

The report provides vital information on biomarkers indentified amid patients receiving VEG-inhibitor therapies, including their description and explanation. The research offers full coverage of over ten cancers and indicates and classifies associations of drug types together with comparative therapies. Besides, clinical trial findings can also be found in the study.

Report Contents:

EXECUTIVE SUMMARY

CHAPTER 1: BACKGROUND (P.18)

1.1 VEGF Inhibition
1.2 Bevacizumab
1.3 Biomarkers
1.4 This Report

CHAPTER 2 COLORECTAL CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P. 22)

Summary
2.1 Introduction
2.2 Glycoprotein
2.3 Protein
2.4 Protein
2.5 Cells
2.6 Genetic
2.7 Physical
2.8 Genetic
2.9 Protein
2.10 Proteins
2.11 Proteins and Genetic
2.12 Image
2.13 Proteins
2.14 Protein

CHAPTER 3 BREAST CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.42)

Summary
3.1 Introduction
3.2 Protein
3.3 Protein
3.4 Protein
3.5 Protein
3.6 Protein
3.7 Genetic
3.8 Protein

CHAPTER 4 RENAL CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.50)

Summary
4.1 Introduction
4.2 Image
4.3 Protein
4.4 Physical
4.5 Protein
4.6 Body Characteristic

CHAPTER 5 OVARIAN CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.55)

Summary
5.1 Introduction
5.2 Proteins
5.3 Proteins
5.4 Proteins
5.5 Proteins

CHAPTER 6 LUNG CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.60)

Summary
6.1 Introduction
6.2 Physical Parameter
6.3 Protein
6.4 Genetic
6.5 Protein

CHAPTER 7 LIVER CANCER: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.65)

Summary
7.1 Introduction
7.2 Protein
7.3 Image

CHAPTER 8 OTHER CANCERS: CANDIDATE BIOMARKERS IDENTIFIED IN PATIENTS RECEIVING BEVACIZUMAB-CONTAINING THERAPIES (P.71)

Summary
8.1 Introduction
8.2 Proteins
8.3 Proteins
8.4 Protein
8.5 Protein
8.6 Physical
8.7 Physical
8.8 Physical

CHAPTER 9: DISCUSSION (P.80)

9.1 Overview
9.2 Colorectal Cancer
9.3 Breast Cancer:
9.4 Renal Cancer:
9.5 Ovarian Cancer
9.6 Lung Cancer
9.7 Liver Cancer
9.8 Other Cancers
9.9 Conclusions

TABLES

Table 2.1 Candidates biomarkers identified in colorectal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 3.1 Candidates biomarkers identified in breast cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 4.1 Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 5.1 Candidates biomarkers identified in ovarian cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 6.1 Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 7.1 Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 8.1 Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.1 Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.2 Genetic candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.3 Image-based candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.4 Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

FIGURES

Figure 9.1 Candidate biomarkers types identified in cancer patients receiving bevacizumab-containing therapies
Figure 9.2 Cancer types evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies
Figure 9.3 Author countries (identified in this report) of cancers evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

More new market research reports by the publisher can be found at Biopharm Reports page.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website